P
Paradigm Biopharma
0 followers
Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.
Org chart
Paul Rennie
Founder & Chairman
Collapse
Simon White
Director of Investor Relations
Michelle Coffey
Global Head of Regulatory Affairs
Donna Skerrett
Chief Medical Officer and Executive Director
Catherine Stapledon
R&d Translational Scientist
Jill Forrest
Clinical Operations Lead
Samantha H.
Director Of Business Operations
Board & advisors
John Gaffney
Non-Executive Director
Amos Meltzer
Non-Executive Director
Kevin Hollingsworth
Company Secretary
Teams
Offices
Similar companies
Arthritis Knee Pain Centers
2 followers
Harrison.ai
3 followers
AstraZeneca
364 followers
Bayer
280 followers
Bristol-Myers Squibb
221 followers
UCB
41 followers
Astellas Pharma
34 followers
NYU Langone Health
16 followers
Tilray
13 followers
Perrigo
12 followers
West Pharmaceutical Services
7 followers
Explore companies